Body mass index (BMI) is
Introduction
Adult obesity is an important determinant of coronary disease risk, type II diabetes, hyperlipidaemia, hypertension and other disease susceptibility in later life. 1 In epidemiological studies, the Quetelet body mass index (BMI), defined as weight (kg)/height (m 2 ) has been widely used as a standard economically obtained surrogate for obesity. Used carefully, (not between genders nor across ethnic groups) it permits broad comparisons of fat mass. 40% excess weight confers a 5-7 fold increased risk, but there is a continuous and steepening gradient of increased risk for BMI > 30 kg/ m 2 . Central (abdominal) obesity is thought to be the most distinctive mark of a 'metabolic syndrome' which is characterised by a clustering of many insulin-resistant cardiovascular risk factors such as hypertension, hypertriglyceridaemia, low HDL-cholesterol, abnormal glucose metabolism and hyperinsulinaemia.
is a polygenic disorder, with only a small variance in phenotype accounted for by individual genes. Despite this, the proportion of people affected due to such genes may be large because they are quite frequent in the population, which makes them of public health significance. These genes seem to operate through modifying susceptibility; the occurrence of the gene increases the risk of developing a characteristic but is not essential for its expression, nor is it itself sufficient to explain the development of the disease. Differences in genetic susceptibility within a population may therefore determine which individuals are most likely to become obese in any given set of environmental circumstances. No human obesity gene has yet been characterised, although a number of candidate genes have been identified which are associated with the obese phenotype. 4, 5 The polygenic basis of obesity traits may best be determined by association, but this demands candidate selection based on linkage, known function or animal studies. The insulin-like growth factors (IGF-I and IGF-II) play a key role in mammalian growth, influencing foetal cell division and differentiation, and possibly metabolic regulation. 6 In the human, unlike in the mouse, IGF2 gene expression continues post-natally, but the significance of this is unknown. However, based on the premise that factors essential for foetal development may also have a role in later life, together with an established association between IGF-I levels and obesity, 7 we previously investigated the relationship between an ApaI polymorphic marker in the IGF2 gene 8 and BMI in over 2500 middle-aged males in the Northwick Park Heart Study II (NPHSII). 9 IGF2 ApaI rare AA homozygotes showed a mean body weight 3.3 kg lower than ApaI common GG homozygotes with heterozygotes intermediate (P = 0.0002). We believe this to be the first large cohort study of adults to establish a positive association between a common variation of a genomic region and obesity in the general population. Continuing the theme of population-scale association study, we have extended our initial observations and establish here novel relationships between markers in the tyrosine hydroxylase-insulin-IGF2 gene region of chromosome 11p15 and population obesity.
The INS promoter variable number tandem repeat (VNTR) class I/III genotype has been shown by others to associate with type I diabetes, 10 obesity, 11 polycystic ovary syndrome obesity 12 and growth in early life, 13 and at least for type I diabetes is aetiological. 10 The INS VNTR locus is 596 bp 5' to the INS start site, and arises from tandem repetition of a 14-15 bp oligonucleotide consensus sequence. 14 The VNTR has been divided into three distinct classes I, II and III according to the number of repeats of the oligonucleotide, measured by Southern blotting. 15 17 We aimed to find out first whether an association between INS VNTR class I/III alleles and BMI existed in the NPHSII cohort and secondly to examine the possibility that INS VNTR class I allele size associates independently with weight or BMI.
Materials and Methods

Study Samples
The Northwick Park Heart Study II (NPHSII) sample comprises healthy adult males aged 50-61 years, 18 with the following exclusions: a history of unstable angina or MI, regular anticoagulant medication, cerebrovascular disease, malignancy, or other conditions precluding informed consent. An unselected group of 2331 from nine widespread UK general practices was studied here.
-23/HphIINS ARMS PCR and Genotyping
The -23/HphI polymorphic site is situated at nucleotide 4462 on GenBank sequence L15440. The rare allele (non-cutting) sequence TCTCC is given in GenBank; the transition T > A creates the common allele (cutting) sequence TCACC. Specific A alleles were PCR-amplified using forward primer HPHA1: 5'-CTTCAGCCTGCCTCAGCCCTGCCTGTGA -3', and specific T alleles were PCR-amplified using forward primer HPHA2: 5'-CTTCAGCCTGCCTCAGCCCTGCC-TGTTT-3', where italicised bases are destabilising mismatches with target, and bases in bold type match the specific allele. The common reverse primer was HPHC: 5'-GGCGGGTCTTGGGTGTGTAGAAGAAGCC-3', giving an ARMS product of size 216 bp. Primers for the control PCR reaction amplified a 360 bp region in the human PCR products were electrophoresed on a 5% polyacrylamide microplate array diagonal gel electrophoresis (MADGE) gel, 20 in TBE buffer at 150V for 20 min. Gels were post-stained in ethidium bromide and examined using a FluorImager® 595 fluorescent scanning system (Molecular Dynamics, Sunnyvale, CA, USA). The images were viewed using Image Quant™ fragment analysis software (Molecular Dynamics) and printed on a Model HP-4M Laserprinter (Hewlett Packard, Palo Alto, CA, USA).
INS 5' VNTR Class I PCR and Allele Size Determination
Class I/III status was confirmed with reference to the -23/HphI genotype. Specific INS class I VNTR alleles differing by a repeat unit (14-15 bp) were PCR-amplified according to the method of Bennett et al, 10 using forward primer 5'-TCAGGCTGGACCTCCAGGTGCCTGTTCTGT-3', reverse primer 5'-TCGTCAGCACCTCTTCCTCAGGACCA-GC-3'. Primers were obtained from Genosys (Cambridge, UK). PCR amplification (1 cycle at 94°C for 10 min, and then 94°C for 1 min and 72°C for 5 min for 30 cycles) was in 96-well Omniplates (Hybaid, Teddington, UK), each 20 µl reaction containing approx 80 ng of DNA, 6.7 mM MgCl 2 , 2 µl 10 ϫ ammonium based reaction buffer (Bioline, London, UK), 10% glycerol, 1.5 mM each dNTP, 10 pmol each primer and 2.5 U of Taq polymerase (Gibco, UK). Each PCR product was reduced in length by 450 bp by digesting 8 µl of each reaction with 2U of NcoI (New England Biolabs, Beverly, Md, USA) in a total volume of 10 µl for 2 h at 37°C according to the supplier's instructions.
NcoI digest samples were diluted 1:9 in water. The gel loading buffer contained formamide dye mix (98% v/v formamide, 50 mM EDTA, and xylene cyanol) and φX 174 DNA-Hae III digest ladder (New England Biolabs) diluted 1:499 in water and mixed in the ratio of 2:1 v/v dye:ladder. A volume of 5 µl of 1/10 dilution of NcoI digest was mixed with 3 µl loading buffer, and 5 µl of this was loaded on to the gel. We used the 96-well MADGE polyacrylamide gel system 20 with electrophoretic conditions which enable resolution of the 15 common INS VNTR alleles over a short (less than 24 mm) track length. Using FluorImager 595® technology, the internal size markers, and sensitive fluorescent post-staining, we have produced resolution and accurate sizing of bands representing differences of one tandem repeat.
Statistical Analysis
Hardy-Weinberg equilibrium and significance of difference between INS 5' VNTR class I allele size frequency distribution in different samples were examined by 2 test. Comparison of continuous variables in the NPHSII sample with respect to IGF2 and INS RFLP genotypes was by one-way ANOVA. Association between mean (log e BMI) and INS VNTR class I allele size was examined by backward stepwise regression. Table 2 displays how variables were coded for each INS VNTR genotype and describes the regression modelling used. The contribution of VNTR class I alleles to the variation in the BMI was estimated using the value of R 2 from the final regression model.
Results
Tests of association between the INS -23/HphI genotype weight and body mass index (BMI) in the NPHSII sample are shown in Table 1 , together with results for INS + 1227/PstI and IGF2 ApaI obtained previously. 9 There was no significant difference in these parameters 10, 22 In the NPHSII cohort, the INS 5' VNTR class I allele size frequency distribution conformed to a pattern characteristically similar to that observed by Bennett et al 10 in parents of diabetics, and therefore the same nomenclature of subclasses is used here.
The association between INS VNTR class I allele size and BMI was investigated using backward stepwise regression of Y = (log e BMI) on X ( Table 2 ). The mean (log e BMI) in the non-carriers of the class I allele, ie class III/III homozygotes is 3.282 units or a mean BMI of 26.64 kg/m 2 . For class I/III heterozygotes, the single class I allele lowers mean BMI compared with the noncarriers, to an extent determined by the size of the class I allele (P < 0.0001). The smaller the allele size, the greater the difference in mean BMI between heterozygotes and non-carriers. For homozygotes, the effect of possessing two class I alleles is also to lower mean BMI, dependent on allele size, but possession of one class I allele is almost identical to possession of two class I alleles of that same size or averaging the same size. The model provides evidence that the class I effect is dominant rather than co-dominant (P < 0.0001) and shows that this effect on BMI depends on the size of the class I alleles involved (P = 0.0002). Figure 1 shows the relationship between mean (log e BMI) and class I allele size. All class I alleles are considered, such that same size class I homozygotes contribute twice to the mean (log e BMI) determination. The gradient of the line of best fit is 0.000234 log e BMI units per bp. Hence a 14 bp tandem repeat increase in allele size corresponds to a 0.00327 unit increase in log e BMI or a 0.33% (95% confidence interval CI = 0.13%, 0.50%) increase in BMI. Over the whole range of class I allele sizes, (641 to 843 bp), this corresponds to a mean increase of 0.0472 units in log e BMI. With mean estimated BMI of 25.32 kg/m 2 at 641 bp and 26.55 kg/m 2 at 843 bp this corresponds to an increase in absolute BMI of 4.83% (95% CI = 2.29%, 7.44%) over the range of class I allele sizes. The sizes of standard errors on the mean reflect the relative frequencies of the alleles. The distribution of points may be alternatively construed as bimodal, and the implications of this are considered below.
Discussion
We have shown that there is no association between INS VNTR class I/III alleles and BMI in a large sample of middle-aged men. The IGF2 ApaI polymorphism which we investigated previously 9 is not in linkage disequilibrium with INS VNTR class I/class III alleles, and therefore must represent an independent association with BMI. However, in this study we have shown . From the regression model, the estimated mean (log e BMI) for carriers of one class I allele is: 3.282539 + (-0.201162) + 0.000234 × allele size = 3.081377 + 0.000234 × allele size. For homozygotes, two class I alleles also lowers mean BMI dependent on allele size. Estimated mean (log e BMI) for carriers of two class I alleles is: 3.282539 + 2(-0.201162) + 0.201606 + 0.000234 × average allele size = 3.081821 + 0.000234 × average allele size. One class I allele has almost identical effect to two class I alleles of that same size or averaging the same size. Comparing like alleles, X 2 effectively cancels out the additive allele effect constrained by X 1 , ie evidence that the class I effect is dominant (P<0.0001). This allows the replacement of X 1 and X 2 with just one variable, X 5 . Replacing X 1 and X 2 with X 5 in the model provides evidence for a dominant effect of class I allele size on BMI (P<0.0001). The significance of X 3 in the model (P=0.0002) shows that this effect depends on the size of the class I alleles involved.
an association between INS VNTR class I allele size and BMI which parallels that which we previously found with IGF2 ApaI. The absence of association between INS VNTR class I/III genotype and BMI in the presence of association between INS VNTR class I allele size and BMI is compatible with the expectation that VNTR class I/III genotype would not reveal an association with BMI which depends on class I allele size associated with 5% variation. A positive signal could be evident in a much larger study, but our investigation, based on over 2500 individuals demonstrates a within-class I effect more striking than one between class I and III. The association between INS VNTR class I allele size and BMI is evident in each of the three IGF2 ApaI genotype groups. Post hoc examination of the combinatoric subgroups does not identify any single haplotype with distinctive weight effect. However, it is apparent that a haplotype containing tyrosine hydroxylase (TH) HUMTH01 microsatellite allele 9, which is in strong linkage disequilibrium with the INS VNTR class I small subclass alleles 21 and with which IGF2 ApaI A alleles are preferentially associated 22 may be important. This raises an alternative explanation of the data, which is that the 'noisy' regression line observed is instead a 'noisy' step (ie bimodality), and that this haplotype contains an aetiological site for low weight. The simplest hypothesis would then be an as yet unidentified single nucleotide polymorphism accounting for the weight variance observed. Many have considered the VNTR aetiological of various phenotypes, [10] [11] [12] [13] but recently others, including the original groups, have come to question the evidence that the VNTR is an aetiological site. 23, 24 The uncertainty of a conclusion of linear regression vs bimodal step obliges examination of a wider genomic region. We have analysed the distribution of IGF2 ApaI alleles with respect to INS VNTR class I alleles, and found an apparent clustering of IGF2 ApaI AA genotypes with the VNTR class I small size subclass (not shown). Taken as a whole our results suggest that there is no partitioning of IGF2 ApaI alleles with respect to INS VNTR class I/III genotype, only with respect to class I allele size. Recently Sharma et al 25 have reported a positive association between HUMTH01 allele 9 and low blood pressure in a case-control association study of hypertension. Although they did not study obesity phenotypes this would be consistent with our finding of IGF2 ApaI A allele and INS VNTR class I small subclass association with low BMI, since central obesity is distinctive of a 'metabolic syndrome' characterised by several cardiovascular risk factors which include hypertension. 2 Several examples exist wherein the number of repeat units within a gene influence function. Triplet repeat length correlates with disease severity and explains anticipation in several loci causing severe neurological disorders 26 and length of a triplet repeat in the androgen receptor gene also influences prostatic cancer risk and age of onset. 27 Gavish et al 28 showed that the variable number of kringle IV-like domains encoded by the gene encoding apo (a) is the main factor determining plasma concentration of lipoprotein (a), and with it susceptibility to cardiovascular disease. The correlation of INS VNTR class I repeat number with BMI represents the first apparent quantitative identification of a correlation of a human minisatellite length with a quantitative phenotype. Previous studies have mainly been dichotomous classifications, disease vs control and class I vs class III. Pur-1 transcription factor is known to bind the repeat, 29 but the possible mechanism of the length correlation remains obscure. The simplest hypothesis based on the known biological effects is that lengthening VNTR increases Pur-1 driven INS transcription, increasing insulin levels and therefore promoting lipogenesis. A comparable hypothesis has been invoked for the differential effects of class I vs class III seen in the qualitative state of type 1 diabetes, although 31 found the IGF2 ApaI G allele (associated with increased BMI in our studies) was associated with significantly higher IGF2 mRNA levels than the A allele, but unlike Paquette et al in placenta and liver cells, found no difference in expression of leukocyte IGF2 with respect to INS VNTR class I/III genotype, as they had previously established in thymus and pancreas. 32 Since our results show no association between INS VNTR I vs III classification and BMI, but substantial association with class I small subclass alleles (in coupling with IGF2 ApaI A alleles) versus large subclass alleles (in coupling with IGF2 ApaI G alleles), a precise aetiological chain between IGF2 and INS mRNA and hormone expression and protection from obesity (the IGF2 ApaI A/INS VNTR class I small subclass haplotype) cannot yet be inferred, although its genetic susceptibility is already measurable. The most plausible hypothesis may be that there is increased average transcription and IGF-II secretion from liver. At least 1.1% of total population BMI variance is accounted for by the present study. As high throughput genome analysis programs gather pace, in conjunction with the genetic study of cohorts, other comparable genomic regions will eventually be identified. Fifty such genetic markers acting in conjunction could account for much of individual and hence population weight variance. This would be a genotype analogue of the use of cholesterol assays in cardiovascular multiple risk assessment and the selection of subjects for risk reduction. 33 A molecular classification of obesity susceptibility pathways (metabolism, regulation, central nervous system etc) may define new targets for therapy and subgroups of the population most likely to be responsive to tailored approaches in preventive medicine.
